Kazakhstan vs Libya: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
Kazakhstan
0.2%
in 2024
Libya
0.2%
in 2024
Kazakhstan rank
78th
Libya rank
78th
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- Kazakhstan
- Libya
How they compare
Kazakhstan currently reports 0.2% against 0.2% in Libya, a difference of 0.0%.
Across all 10 years both countries report, Libya has been ahead every year.
Kazakhstan ranks 78th and Libya ranks 78th of 215 countries.
Head to head by decade
| Decade | Kazakhstan | Libya | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.2% | 0.2% | 0.0% | — |
| 2020s | 0.2% | 0.2% | 0.0% | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Kazakhstan or Libya?
- Kazakhstan, at 0.2% against 0.2% in Libya as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Kazakhstan and Libya?
- 0.0%, with Kazakhstan ahead.
- How many years of comparable data are there for Kazakhstan and Libya?
- 10 years are reported by both, from 2015 to 2024.
- How do Kazakhstan and Libya rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- Kazakhstan ranks 78th and Libya ranks 78th of 215 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.